Work

S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e15007

Authors: Gilles Tapolsky, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, Anne M. Noonan, John L. Villano, Richard Charles Curry, Carolyn Muller, Trisha Michel Wise-Draper, Vinay K. Puduvalli, Ray Takigiku

Institutions: Bexion Pharmaceuticals (United States), University of Cincinnati, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Montefiore Medical Center, The Ohio State University, University of Kentucky, University of New Mexico, The Ohio State University Wexner Medical Center

Language: English

Topic: Sphingolipid Metabolism and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281712293

Cites:

Cited by: 1

Related to: 10